The Zotect study: Effect of zoledronic acid (Zometa®) on Bone Metabolism in Patients with Nreast or Prostate cancer with Bone metastases.

被引：0
|
作者：
Gschwendt, J. [1 ]
Ziller, M. [2 ]
Kalder, M. [2 ]
Lux, C. [1 ]
Maurer, T. [1 ]
Muth, M. [3 ]
Schmidt, K. [3 ]
Hadji, P. [2 ]
机构：
[1] Klinikum RD Isar, Urol Klin, Munich, Germany
[2] Univ Marburg, Marburg, Germany
[3] Novartis Pharma GmbH, BU Onkol, Nurnberg, Germany
来源：
ONKOLOGIE | 2010年 / 33卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：204 / 204
页数：1
相关论文
共 50 条
  • [41] Administration of zoledronic acid before the onset of bone pain may be more effective in patients with bone metastases from prostate cancer
    Saad, F.
    Gleason, D.
    Chen, Y. M.
    Eastham, J.
    CANCER TREATMENT REVIEWS, 2006, 32 : S33 - S33
  • [42] Repeated dose samarium 153 lexidronam in patients with prostate cancer bone metastases.
    Sartor, AO
    Reid, R
    Higano, C
    Bushnell, D
    Quick, D
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 411S - 411S
  • [43] Effect of zoledronic acid on serum angiogenic factors in patients with bone metastases
    Faruk Tas
    Derya Duranyildiz
    Hilal Oguz
    Hakan Camlica
    Vildan Yasasever
    Erkan Topuz
    Medical Oncology, 2008, 25 : 346 - 349
  • [44] Breast cancer bone metastases: denosumab or zoledronic acid?
    Gabri van der Pluijm
    Nature Reviews Endocrinology, 2011, 7 : 134 - 135
  • [45] Zoledronic acid in lung cancer with bone metastases: a review
    Isla, Dolores
    Afonso, Ruth
    Bosch-Barrera, Joaquim
    Martinez, Natividad
    EXPERT REVIEW OF ANTICANCER THERAPY, 2013, 13 (04) : 421 - 426
  • [46] Clinically relevant molecular subgroups of prostate cancer bone metastases.
    Thysell, Elin
    Ylitalo, Erik Bovinder
    Jernberg, Emma
    Crnalic, Sead
    Widmark, Anders
    Bergh, Anders
    Wikstrom, Pernilla
    CANCER RESEARCH, 2018, 78 (16) : 123 - 123
  • [47] CANCER Breast cancer bone metastases: denosumab or zoledronic acid?
    van der Pluijm, Gabri
    NATURE REVIEWS ENDOCRINOLOGY, 2011, 7 (03) : 134 - 135
  • [48] Zoledronic acid compliance and persistency in bone metastases due to breast, lung, and prostate cancer
    Feinberg, B. A.
    Gilmore, J. W.
    Saleh, M. N.
    Gondesen, T.
    Jackson, J.
    Barghout, V.
    Mody-Patel, N.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [49] Androgen deprivation causes bone loss and increased prostate cancer metastases to bone: Prevention by zoledronic acid.
    Padalecki, SS
    Carreon, MR
    Grubbs, B
    Cui, Y
    Guise, TA
    JOURNAL OF BONE AND MINERAL RESEARCH, 2002, 17 : S310 - S310
  • [50] A new parameter of bone scintigraphy: Relation between bone scan index and bone metabolic markers in prostate cancer patients with bone metastases.
    Wakabayashi, Hiroshi
    Nakajima, Kenichi
    Mizokami, Atsushi
    Namiki, Mikio
    Inaki, Anri
    Taki, Junichi
    Kinuya, Seigo
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
12345